SB101
Asset
siRNA knockdown reverses cellular epigenetic aging and ameliorates fibrosis.
- Stage
- Preclinical
- Modality
- Oligonucleotide
- Target
- Not known
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Liver fibrosis
Preclinical, shiftbioscience.com, 10 Oct 2026
In the full profile
- Owner and partners1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.